JO3148B1 - مركب مثبط لإشارات مسار notch - Google Patents

مركب مثبط لإشارات مسار notch

Info

Publication number
JO3148B1
JO3148B1 JOP/2012/0190A JOP20120190A JO3148B1 JO 3148 B1 JO3148 B1 JO 3148B1 JO P20120190 A JOP20120190 A JO P20120190A JO 3148 B1 JO3148 B1 JO 3148B1
Authority
JO
Jordan
Prior art keywords
signaling inhibitor
notch pathway
pathway signaling
inhibitor compound
compound
Prior art date
Application number
JOP/2012/0190A
Other languages
English (en)
Inventor
Alan Stephenson Gregory
Arthur Hipskind Philip
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of JO3148B1 publication Critical patent/JO3148B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

يوفر الاختراع الحالي مركب، أو ملح أو هيدرات مقبولين صيدليًا، وتركيبة صيدلية تحتوي على المركب المذكور، أو ملح أو هيدرات مقبولين صيدليًا، ويكون مفيدًا كمثبِّط لإشارات مسار Notch لعلاج السرطان.
JOP/2012/0190A 2011-07-27 2012-07-10 مركب مثبط لإشارات مسار notch JO3148B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161512016P 2011-07-27 2011-07-27
US201161560486P 2011-11-16 2011-11-16

Publications (1)

Publication Number Publication Date
JO3148B1 true JO3148B1 (ar) 2017-09-20

Family

ID=46598983

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2012/0190A JO3148B1 (ar) 2011-07-27 2012-07-10 مركب مثبط لإشارات مسار notch

Country Status (36)

Country Link
US (1) US8569286B2 (ar)
EP (1) EP2736920B1 (ar)
JP (1) JP6027110B2 (ar)
KR (1) KR101578309B1 (ar)
CN (1) CN103732612B (ar)
AP (1) AP4080A (ar)
AR (1) AR087107A1 (ar)
AU (1) AU2012287251B2 (ar)
BR (1) BR112014001600B1 (ar)
CA (1) CA2841178C (ar)
CL (1) CL2014000175A1 (ar)
CO (1) CO6862159A2 (ar)
CR (1) CR20140036A (ar)
CY (1) CY1116645T1 (ar)
DK (1) DK2736920T3 (ar)
DO (1) DOP2014000011A (ar)
EA (1) EA023044B1 (ar)
EC (1) ECSP14013179A (ar)
ES (1) ES2544937T3 (ar)
GT (1) GT201400012A (ar)
HK (1) HK1194086A1 (ar)
HR (1) HRP20150771T1 (ar)
HU (1) HUE027534T2 (ar)
IL (1) IL229988A (ar)
JO (1) JO3148B1 (ar)
MA (1) MA35611B1 (ar)
ME (1) ME02171B (ar)
MX (1) MX356536B (ar)
MY (1) MY184303A (ar)
PE (1) PE20141061A1 (ar)
PL (1) PL2736920T3 (ar)
PT (1) PT2736920E (ar)
RS (1) RS54135B1 (ar)
SI (1) SI2736920T1 (ar)
TW (1) TWI568730B (ar)
WO (1) WO2013016081A1 (ar)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10350216B2 (en) 2013-01-14 2019-07-16 The Trustees Of Columbia University In The City Of New York Methods of treating, preventing and diagnosing leukemia and other blood diseases and disorders
CN105764501A (zh) 2013-07-26 2016-07-13 现代化制药公司 改善比生群治疗效益的组合物
TWI704151B (zh) 2014-12-22 2020-09-11 美商美國禮來大藥廠 Ｅｒｋ抑制劑
TWI609687B (zh) 2015-04-14 2018-01-01 美國禮來大藥廠 平滑肌肉瘤之標靶性治療
TWI625332B (zh) * 2015-07-07 2018-06-01 美國禮來大藥廠 刻痕（ｎｏｔｃｈ）路徑傳訊抑制化合物
EP3414239A2 (en) 2016-02-05 2018-12-19 Denali Therapeutics Inc. Inhibitors of receptor-interacting protein kinase 1
EA201892075A1 (ru) 2016-03-15 2019-04-30 Оризон Дженомикс, С.А. Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей
RU2747788C2 (ru) * 2016-04-12 2021-05-14 Эли Лилли Энд Компани Комбинированная терапия ингибиторами notch и cdk4/6 для лечения рака
US11564929B2 (en) 2016-04-12 2023-01-31 Eli Lilly And Company Combination therapy with Notch and PI3K/mTOR inhibitors for use in treating cancer
ES2904880T3 (es) * 2016-05-20 2022-04-06 Lilly Co Eli Terapia combinada con inhibidores de Notch y de PD-1 o PD-L1
CA3035616A1 (en) * 2016-08-31 2018-03-08 Eli Lilly And Company Dosage regimen for treatment of solid tumors
WO2018071307A1 (en) 2016-10-12 2018-04-19 Eli Lilly And Company Targeted treatment of mature t-cell lymphoma
PL3552017T3 (pl) 2016-12-09 2022-08-08 Denali Therapeutics Inc. Związki użyteczne jako inhibitory RIPK1
CA3052779A1 (en) 2017-02-17 2018-08-23 Fred Hutchinson Cancer Research Center Combination therapies for treatment of bcma-related cancers and autoimmune disorders
KR20200116077A (ko) 2017-11-01 2020-10-08 주노 쎄러퓨티크스 인코퍼레이티드 B 세포 성숙 항원에 특이적인 키메라 항원 수용체 및 암호화 폴리뉴클레오타이드
WO2019090364A1 (en) * 2017-11-06 2019-05-09 Juno Therapeutics, Inc. Combination of a cell therapy and a gamma secretase inhibitor
SG11202011041YA (en) * 2018-05-06 2020-12-30 Ayala Pharmaceuticals Inc Combination compositions comprising bisfluoroalkyl-1,4- benzodiazepinone compounds and methods of use thereof
KR20210084484A (ko) 2018-10-02 2021-07-07 프리퀀시 테라퓨틱스, 인크. 귀 치료제를 포함하는 약제학적 조성물 및 관련 방법
CN114340611A (zh) 2019-04-08 2022-04-12 频率医疗公司 用于治疗听力损失的chir99021和丙戊酸的组合

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9711537B (en) * 1996-12-23 1998-06-25 Athena Neurosciences Inc Eli L Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting ß-amyloid peptide release and/or its synthesis by use of such compounds.
JP2002518481A (ja) 1998-06-22 2002-06-25 エラン ファーマシューティカルズ，インコーポレイテッド β−アミロイドペプチドの放出および／またはその合成を阻害するための化合物
WO1999067221A1 (en) * 1998-06-22 1999-12-29 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
PL378405A1 (pl) 2003-02-04 2006-04-03 F. Hoffmann-La Roche Ag Pochodne malonoamidu jako inhibitory <$Egamma> - sekretazy
KR100838852B1 (ko) 2003-09-09 2008-06-16 에프. 호프만-라 로슈 아게 감마-세크리테이즈의 활성을 차단하는 말론아미드 유도체
KR100884872B1 (ko) 2003-10-06 2009-02-23 에프. 호프만-라 로슈 아게 감마-세크레타제 저해제로서 유용한 치환된다이벤조-아제핀 및 벤조-다이아제핀 유도체
CA2645756C (en) 2006-03-27 2013-12-31 F. Hoffmann-La Roche Ag Malonamide derivatives as gamma secretase inhibitors
CN101622232A (zh) * 2007-02-02 2010-01-06 弗·哈夫曼-拉罗切有限公司 6-氧代-6,7-二氢-5h-二苯并[b,d]氮杂䓬-7-基衍生物
MA33076B1 (ar) 2008-01-11 2012-03-01 Hoffmann La Roche استخدام مثبط غاما-سكريتيز لعلاج السرطان
US8637493B2 (en) * 2009-11-12 2014-01-28 University Of Massachusetts Methods for treating glioblastoma

Also Published As

Publication number Publication date
KR20140026624A (ko) 2014-03-05
ME02171B (me) 2015-10-20
KR101578309B1 (ko) 2015-12-16
EA023044B1 (ru) 2016-04-29
BR112014001600A2 (pt) 2017-02-21
HK1194086A1 (en) 2014-10-10
JP6027110B2 (ja) 2016-11-16
CA2841178C (en) 2016-12-20
HUE027534T2 (en) 2016-11-28
MY184303A (en) 2021-03-31
AR087107A1 (es) 2014-02-12
IL229988A (en) 2017-07-31
CO6862159A2 (es) 2014-02-10
TWI568730B (zh) 2017-02-01
PL2736920T3 (pl) 2015-11-30
HRP20150771T1 (hr) 2015-08-28
MX356536B (es) 2018-06-01
US8569286B2 (en) 2013-10-29
NZ618891A (en) 2015-12-24
SI2736920T1 (sl) 2015-08-31
AP2014007362A0 (en) 2014-01-31
WO2013016081A1 (en) 2013-01-31
CL2014000175A1 (es) 2014-08-22
EP2736920A1 (en) 2014-06-04
CR20140036A (es) 2014-03-21
TW201315732A (zh) 2013-04-16
CN103732612B (zh) 2015-09-23
BR112014001600B1 (pt) 2022-09-13
AU2012287251A1 (en) 2014-01-30
CA2841178A1 (en) 2013-01-31
ECSP14013179A (es) 2014-03-31
PE20141061A1 (es) 2014-09-06
DOP2014000011A (es) 2014-07-31
EA201490161A1 (ru) 2014-04-30
ES2544937T3 (es) 2015-09-07
MA35611B1 (fr) 2014-11-01
EP2736920B1 (en) 2015-07-01
PT2736920E (pt) 2015-09-16
GT201400012A (es) 2014-07-16
DK2736920T3 (en) 2015-07-20
RS54135B1 (en) 2015-12-31
CN103732612A (zh) 2014-04-16
JP2014527042A (ja) 2014-10-09
AU2012287251B2 (en) 2015-05-14
MX2014001084A (es) 2014-02-27
CY1116645T1 (el) 2017-03-15
US20130029972A1 (en) 2013-01-31
AP4080A (en) 2017-03-29

Similar Documents

Publication Publication Date Title
JO3148B1 (ar) مركب مثبط لإشارات مسار notch
SA515360469B1 (ar) مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها
MX2013011329A (es) Combinaciones de compuestos inhibidores de akt y erlotinib y metodos de uso.
UA117976C2 (uk) Сполуки амінопіримідинілу як інгібітори jak
PH12015500064A1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
TN2014000016A1 (en) 4 - piperidinyl compounds for use as tankyrase inhibitors
IN2014DN10670A (ar)
MD4684B1 (ro) Formulări pe bază de imidazopirazine în calitate de inhibitori SYK
MX2011009796A (es) Inhibidores de la cinasa pi3.
MX2013007336A (es) Compuestos de bi-heteroarilo como inhibidores de vps34.
PH12014502492A1 (en) Pyrazole compounds as sglt1 inhibitors
MX362896B (es) Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cáncer.
MX362879B (es) Usos novedosos.
MX2015007940A (es) Compuestos tricíclicos como inhibidores de cftr.
JO3145B1 (ar) مركبات مفيدة لتثبيط chk1
MX2016006667A (es) Derivados de pirrolo-pirrolona y su uso como inhibidores.
TN2013000515A1 (en) Notch pathway signaling inhibitor compound
UA110834C2 (uk) Сполука-інгібітор сигнального шляху notch